Korea SPAC 2 (206400) - Total Liabilities

Latest as of September 2025: ₩6.45 Billion KRW ≈ $4.37 Million USD

Based on the latest financial reports, Korea SPAC 2 (206400) has total liabilities worth ₩6.45 Billion KRW (≈ $4.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 206400 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Korea SPAC 2 - Total Liabilities Trend (2015–2024)

This chart illustrates how Korea SPAC 2's total liabilities have evolved over time, based on quarterly financial data. See Korea SPAC 2 free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Korea SPAC 2 Competitors by Total Liabilities

The table below lists competitors of Korea SPAC 2 ranked by their total liabilities.

Company Country Total Liabilities
TAS Offshore Bhd
KLSE:5149
Malaysia RM69.16 Million
Victor Group Holdings Ltd
AU:VIG
Australia AU$6.95 Million
Scope Industries Bhd
KLSE:0028
Malaysia RM13.57 Million
Viking Kagit ve Seluloz AS
IS:VKING
Turkey TL3.73 Billion
Greater Than AB
ST:GREAT
Sweden Skr47.90 Million
Medicenna Therapeutics Corp
TO:MDNA
Canada CA$6.85 Million
CEO Event Medya AS
IS:CEOEM
Turkey TL492.00 Million
Jullundur Motor Agency (Delhi) Limited
NSE:JMA
India Rs749.82 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Korea SPAC 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Korea SPAC 2.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 13.31 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.08 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.08 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Korea SPAC 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Korea SPAC 2 (2015–2024)

The table below shows the annual total liabilities of Korea SPAC 2 from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩9.53 Billion
≈ $6.46 Million
-77.87%
2023-12-31 ₩43.06 Billion
≈ $29.18 Million
+37.37%
2022-12-31 ₩31.35 Billion
≈ $21.24 Million
-30.63%
2021-12-31 ₩45.19 Billion
≈ $30.62 Million
+93.55%
2020-12-31 ₩23.35 Billion
≈ $15.82 Million
+122.88%
2019-12-31 ₩10.47 Billion
≈ $7.10 Million
-41.79%
2018-12-31 ₩18.00 Billion
≈ $12.20 Million
+298.54%
2017-12-31 ₩4.52 Billion
≈ $3.06 Million
+29.07%
2016-12-31 ₩3.50 Billion
≈ $2.37 Million
+17.66%
2015-12-31 ₩2.97 Billion
≈ $2.01 Million
--

About Korea SPAC 2

KQ:206400 Korea Electronic Gaming & Multimedia
Market Cap
$21.73 Million
₩32.07 Billion KRW
Market Cap Rank
#24784 Global
#1771 in Korea
Share Price
₩855.00
Change (1 day)
+4.52%
52-Week Range
₩760.00 - ₩2605.00
All Time High
₩21588.39
About

BENO TNR, Inc. engages in interior design, construction, robot, and bio businesses. It engages in the designing, manufacturing, and construction of shading systems, eco-friendly flooring, and radiant heating panels applied to various buildings. It also provides XoMotion, an exoskeleton wearable robot that supports lower body movements; and develops medicine through epigenetic modification. BENO T… Read more